Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL289296 | 0.80 | — | — | |
| SCHEMBL17931805 | 0.77 | OPRM1 (0.32) | GAAL3MBTL1 | |
| SCHEMBL5697668 | 0.69 | GAA (0.35) | GAAL3MBTL1 | |
| SCHEMBL14546083 | 0.69 | GAA (0.35) | GAAL3MBTL1 | |
| SCHEMBL22845266 | 0.67 | — | — | |
| SCHEMBL7559779 | 0.67 | GAA (0.33) | GAAL3MBTL1 | |
| SCHEMBL244419 | 0.64 | GAA (0.39) | GAAL3MBTL1 | |
| SCHEMBL18417981 | 0.63 | CRHBP (0.35) | GAAL3MBTL1 | |
| SCHEMBL10084909 | 0.63 | GAA (0.31) | GAAL3MBTL1 | |
| SCHEMBL16325463 | 0.63 | GAA (0.31) | GAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846674-B2 | Nitric oxide enhancing prostaglandin compounds, compositions and methods of use | NICOX, S.A. (FR) | 2014-09-30 | — | — | US | disclosed |
| US-20120034321-A1 | NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. | 2012-02-09 | — | — | US | disclosed |
| US-8067464-B2 | Compositions and methods using apocynin compounds and nitric oxide donors | NITROMED, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067414-B2 | Nitric oxide enhancing prostaglandin compounds, compositions and methods of use | NICOX S.A. (FR) | 2011-11-29 | — | — | US | disclosed |
| US-7838023-B2 | Furoxan compounds, compositions and methods of use | NITROMED, INC. (US) | 2010-11-23 | — | — | US | disclosed |
| US-20100240622-A1 | NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20090306027-A1 | GENETIC RISK ASSESSMENT IN HEART FAILURE: IMPACT OF THE GENETIC VARIATION OF G-PROTEIN BETA 3 SUBUNIT POLYMORPHISM | NITOMED, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090253662-A1 | GENETIC RISK ASSESSMENT IN HEART FAILURE: IMPACT OF GENETIC VARIATION OF ALDOSTERONE SYNTHASE PROMOTER POLYMORPHISM | NITROMED, INC. (US) | 2009-10-08 | — | — | US | disclosed |
| US-7595313-B2 | Nitric oxide donating diuretic compounds, compositions and methods of use | NICOX, S.A. (FR) | 2009-09-29 | — | — | US | disclosed |
| US-20090215838-A1 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF ANGIOTENSIN II ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090018091-A1 | Nitric Oxide Enhancing Antimicrobial Compounds, Compositions and Methods of Use | NITROMED, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| US-20090012057-A1 | Cardiovascular Compounds Comprising Nitric Oxide Enhancing Groups, Compositions and Methods of Use | NITROMED, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20080306041-A1 | Cardiovascular Compounds Comprising Heterocyclic Nitric Oxide Donor Groups, Compositions and Methods of Use | NICOX S.A. (FR) | 2008-12-11 | — | — | US | disclosed |
| US-20080300292-A1 | Nitrosated and Nitrosylated Compounds, Compositions and Methods for the Treatment of Ophthalmic Disorders | NITROMED, INC (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080293702-A1 | Nitric Oxide Enhancing Pyruvate Compounds, Compositions and Methods of Use | NITROMED, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293678-A1 | Organic Nitric Oxide Donor Salts of Angiotensin Converting Enzyme Inhibitors, Compositions and Methods of Use | NITROMED, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080268014-A1 | Furoxan Compounds, Compositions and Methods of Use | NITROMED, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080255101-A1 | NITRIC OXIDE DONATING DIURETIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-7396829-B2 | such as 2H-1,2,4-benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-3-[5-(nitrooxy)pentyl]-, 1,1-dioxide; contains at least one nitric oxide enhancing group; excessive water or electrolyte retention conditions; cardiovascular diseases, and diseases resulting from oxidative or endothelial dysfunctions | NITROMED, INC. (US) | 2008-07-08 | — | — | US | disclosed |
| US-20070032533-A1 | Nitric oxide enhancing angiotensin II antagonist compounds, compositions and methods of use | NITROMED, INC. (US) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293702-A1 | Nitric Oxide Enhancing Pyruvate Compounds, Compositions and Methods of Use | PC, PDK1, NOS3 | GAA 2877/4885L3MBTL1 2210/4885 |
| US-20090215838-A1 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF ANGIOTENSIN II ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | NOS2, NOS3, NOS1 | GAA 1892/4885L3MBTL1 3906/4885 |
| US-20100240622-A1 | NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE | PTGIS, NOS2, NOS1 | GAA 2233/4885L3MBTL1 4855/4885 |
| US-20080300292-A1 | Nitrosated and Nitrosylated Compounds, Compositions and Methods for the Treatment of Ophthalmic Disorders | NOS3, NOS1, NOS2 | GAA 374/4885L3MBTL1 4813/4885 |
| US-20090012057-A1 | Cardiovascular Compounds Comprising Nitric Oxide Enhancing Groups, Compositions and Methods of Use | REN, EDNRB, ECE1 | GAA 254/4885L3MBTL1 4453/4885 |
| US-20080306041-A1 | Cardiovascular Compounds Comprising Heterocyclic Nitric Oxide Donor Groups, Compositions and Methods of Use | REN, NOX5, NOS3 | GAA 1484/4885L3MBTL1 3468/4885 |
| US-20120034321-A1 | NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE | PTGIS, NOS2, PTGS1 | GAA 2755/4885L3MBTL1 4875/4885 |
| US-20090018091-A1 | Nitric Oxide Enhancing Antimicrobial Compounds, Compositions and Methods of Use | NOS1, NOS3, NOS2 | GAA 1111/4885L3MBTL1 3869/4885 |
| US-20090253662-A1 | GENETIC RISK ASSESSMENT IN HEART FAILURE: IMPACT OF GENETIC VARIATION OF ALDOSTERONE SYNTHASE PROMOTER POLYMORPHISM | HSD11B2, HSD11B1, CYP11B2 | GAA 2955/4885L3MBTL1 1004/4885 |
| US-20080268014-A1 | Furoxan Compounds, Compositions and Methods of Use | PTGIS, F3, PTGIR | GAA 4734/4885L3MBTL1 3969/4885 |
| US-20070032533-A1 | Nitric oxide enhancing angiotensin II antagonist compounds, compositions and methods of use | AGTR2, AGTR1, REN | GAA 762/4885L3MBTL1 4289/4885 |
| US-20080293678-A1 | Organic Nitric Oxide Donor Salts of Angiotensin Converting Enzyme Inhibitors, Compositions and Methods of Use | NOS3, REN, NOS1 | GAA 1190/4885L3MBTL1 3552/4885 |
| US-20090306027-A1 | GENETIC RISK ASSESSMENT IN HEART FAILURE: IMPACT OF THE GENETIC VARIATION OF G-PROTEIN BETA 3 SUBUNIT POLYMORPHISM | ADRB3, GNAI3, GNB1 | GAA 3505/4885L3MBTL1 635/4885 |
| US-20080255101-A1 | NITRIC OXIDE DONATING DIURETIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NOS1, NOS3, NOS2 | GAA 1104/4885L3MBTL1 4408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.